Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at esmo 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity
Filed with HKEX · Stock code 2616 ·
6ix is reading this filing.
View original source (HKEXnews)CStone Pharmaceuticals on 6ix
Earlier from CStone Pharmaceuticals
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Interim report 2026
- Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
- CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
- CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Follow CStone Pharmaceuticals